With the prevalence of hepatic-colorectal metastasis rising worldwide and its strong association with comorbidities such as diabetes, cardiovascular disorders, and certain cancers, there is an increasing need for safer and more effective therapies. DelveInsight reports that over three pharmaceutical and biotech companies are actively advancing more than three therapeutic candidates targeting hepatic-colorectal metastasis. These candidates are progressing through various stages of clinical and preclinical development, reflecting significant innovation and dedication to tackling this critical global health challenge.
The “Hepatic-Colorectal Metastasis Pipeline Insight 2025” report by DelveInsight offers an in-depth strategic review of the current R&D landscape. It examines clinical trial progress, emerging therapies, mechanisms of action, competitive positioning, and major company initiatives. This report is an essential resource for researchers, healthcare investors, and decision-makers seeking insights into the evolving hepatic-colorectal metastasis therapeutics market and the breakthroughs shaping its future.
Explore the Cutting-Edge Landscape of Hepatic-colorectal Metastasis Drug Development
Key Takeaways from the Hepatic-colorectal Metastasis Pipeline Report
-
DelveInsight’s report on the hepatic-colorectal metastasis pipeline highlights a dynamic landscape, with over three active companies developing multiple therapeutic candidates for the treatment of hepatic-colorectal metastasis. On April 8, 2025, the FDA approved the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) as a first-line treatment for unresectable or metastatic MSI‑high/dMMR colorectal cancer, including cases with liver metastases.
-
Leading companies, including Sotevtamab, Nelitolimod, and PDC*Neo, are actively exploring novel therapies to enhance the hepatic-colorectal metastasis treatment landscape. Notable pipeline candidates, such as Sotevtamab and Nelitolimod, are progressing through various stages of development, offering promising options for future patient care.
Hepatic-colorectal Metastasis Overview:
Colorectal cancer (CRC) continues to be a significant global health challenge, ranking as the second most common cancer in women and the third in men, and accounting for roughly 10% of all cancer cases and related deaths worldwide. Advances in early detection, screening programs, surgical methods, chemotherapy, and understanding of tumor biology have contributed to improved survival rates. However, approximately 25% to 50% of CRC patients eventually develop colorectal liver metastases (CRLM), which significantly complicate treatment and prognosis. Management of CRLM has evolved over time, with surgical resection now recognized as a potential curative option. Current care for CRLM patients relies on a multidisciplinary approach, bringing together specialists in radiology, oncology, hepatobiliary and colorectal surgery, pathology, and nursing to optimize patient outcomes. This review explores the latest strategies for diagnosing, staging, and treating CRLM, highlighting recent advancements in chemotherapy, surgical techniques, and biomarker-driven approaches.
When CRC spreads to the liver, it can lead to a range of symptoms, though some patients may remain asymptomatic in the early stages. Common signs include upper right abdominal pain or discomfort, jaundice (yellowing of the skin and eyes), unexplained weight loss, fatigue, and decreased appetite. Other potential symptoms may include fever, nausea, abdominal swelling (ascites), leg swelling (edema), and general weakness. The intensity and type of symptoms usually depend on the extent of liver involvement.
Download the Hepatic-colorectal Metastasis sample report to know in detail about the Hepatic-colorectal Metastasis treatment market
Hepatic-colorectal Metastasis Pipeline Analysis
The Hepatic-colorectal Metastasis pipeline insights report 2025, provides insights into:
-
Provides comprehensive insights into key companies developing therapies in the Hepatic-colorectal Metastasis Market.
-
Categorizes Hepatic-colorectal Metastasis therapeutic companies by development stage: early, mid, and late-stage.
-
Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.
-
Reviews emerging Hepatic-colorectal Metastasis drugs under development based on:
-
Stage of development
-
Hepatic-colorectal Metastasis Route of administration
-
Target receptor
-
Monotherapy vs. combination therapy
-
Hepatic-colorectal Metastasis Mechanism of action
-
Molecular type
-
-
Offers detailed analysis of:
-
Company-to-company and company-academia collaborations
-
Hepatic-colorectal Metastasis Licensing agreements
-
Funding and investment activities supporting future Hepatic-colorectal Metastasis market advancement.
-
Unlock key insights into emerging Hepatic-colorectal Metastasis therapies and market strategies here: https://www.delveinsight.com/report-store/hepatic-colorectal-metastasis-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Hepatic-colorectal Metastasis Emerging Drugs
-
Sotevtamab : Alethia Biotherapeutics
Sotevtamab is a humanized IgG2 monoclonal antibody that specifically targets secreted clusterin (sCLU), a tumor-associated protein that promotes epithelial-to-mesenchymal transition (EMT), a crucial process in cancer metastasis. By blocking EMT, sotevtamab interferes with a key pathway in tumor progression. Preclinical studies have shown that it effectively suppresses EMT, leading to decreased tumor invasiveness and enhanced responsiveness to chemotherapy in cancer models. Early-phase clinical trials in patients with
-
Nelitolimod: TriSalus Life Sciences, Inc.
Nelitolimod is an experimental Toll-Like Receptor 9 (TLR9) agonist under development for treating hepatic-colorectal metastases. It works by activating TLR9 receptors on immune-suppressive and antigen-presenting cells, thereby boosting anti-tumor T-cell responses. Unlike conventional TLR9 agonists that require direct injection into superficial tumors, nelitolimod utilizes TriSalus’ proprietary Pressure-Enabled Drug Delivery™ (PEDD™) system, enabling targeted delivery to deep-seated tumors in organs such as the liver and pancreas through intravascular infusion. This approach aims to strengthen the immune response, enhance the efficacy of immunotherapy, and slow tumor growth. Nelitolimod is currently in the preclinical development stage.
Hepatic-colorectal Metastasis Pipeline Therapeutic Assessment
Hepatic-colorectal Metastasis Assessment by Product Type
• Mono
• Combination
• Mono/Combination
Hepatic-colorectal Metastasis By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
Hepatic-colorectal Metastasis Assessment by Route of Administration
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
Hepatic-colorectal Metastasis Assessment by Molecule Type
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
Download sample pages to get an in-depth assessment of the emerging Hepatic-colorectal Metastasis therapies and key Hepatic-colorectal Metastasis companies
Table of Contents
1. Report Introduction
2. Executive Summary
3. Hepatic-colorectal Metastasis Current Treatment Patterns
4. Hepatic-colorectal Metastasis - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Hepatic-colorectal Metastasis Late-Stage Products (Phase-III)
7. Hepatic-colorectal Metastasis Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Hepatic-colorectal Metastasis Discontinued Products
13. Hepatic-colorectal Metastasis Product Profiles
14. Hepatic-colorectal Metastasis Key Companies
15. Hepatic-colorectal Metastasis Key Products
16. Dormant and Discontinued Products
17. Hepatic-colorectal Metastasis Unmet Needs
18. Hepatic-colorectal Metastasis Future Perspectives
19. Hepatic-colorectal Metastasis Analyst Review
20. Appendix
21. Report Methodology
Request the sample PDF to get detailed insights about the Hepatic-colorectal Metastasis pipeline reports offerings
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
